Sanofi's stock experienced a significant decline, losing over 10% of its value, after disappointing clinical trial results. The experimental drug, amlitelimab, aimed to treat atopic dermatitis (eczema), fell short of expectations. While amlitelimab met its primary goals in the Phase III study, the data was less impressive compared to Dupixent, Sanofi's blockbuster eczema treatment. Investors were concerned about amlitelimab's ability to replace Dupixent, which is facing patent expiration in 2031. Amlitelimab was considered a key asset in Sanofi's pipeline to succeed Dupixent, hence the strong reaction. The drug is meant to be part of Sanofi's focus on immunology. Dupixent, jointly developed with Regeneron, is approved for various conditions and generated substantial sales for Sanofi. Analysts noted amlitelimab's efficacy was weaker than Dupixent's but highlighted its potential based on safety and dosing convenience. Despite weaker efficacy, the drug's less frequent dosing may benefit injection-averse patients.